Home › Gastrointestinal Stromal Tumors › Washington › Seattle
Gastrointestinal Stromal Tumors clinical trials in Seattle, WA
4 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RecruitingPhase 3
- GSK Investigational Site, Seattle
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
RecruitingPhase 3
- GSK Investigational Site, Seattle
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- University of Washington School of Medicine, Seattle
Gastrointestinal Stromal Tumors trials in other cities
- Miami, FL8 studies
- Boston, MA7 studies
- New York City, NY7 studies
- Philadelphia, PA6 studies
- Houston, TX6 studies
- Nashville, TN5 studies
- San Diego, CA5 studies
- Portland, OR5 studies
- Omaha, NE5 studies
- Durham, NC4 studies
- Dallas, TX4 studies
- Jacksonville, FL4 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia41 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Bladder Cancer21 studies
- Myelodysplastic Syndromes21 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.